TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a conference call at 10:00 AM EDT on Tuesday, August 7, 2012 to review second quarter 2012 results. The quarterly results will be released on the Company’s website (www.cgen.com), prior to the conference call.
To access the conference call, please dial 1-888-668-9141 from the US, or + 972-3-9180609 internationally. The call will also be available via live webcast through Compugen’s website, located at the following link.
A replay of the conference call will be available approximately two hours after the completion of the live conference call. To access the replay, please dial 1-888-326-9310 from the US or +972-3-925-904 internationally. The replay will be available through August 10, 2012.
About Compugen
Compugen is a leading therapeutic product
discovery company focused on therapeutic proteins and monoclonal
antibodies to address important unmet needs in the fields of immunology
and oncology. Unlike traditional high throughput trial and error
experimental based drug candidate discovery, Compugen utilizes a broad
and continuously growing infrastructure of proprietary scientific
understandings and predictive platforms, algorithms, machine learning
systems and other computational biology capabilities for the in silico
(by computer) prediction and selection of product candidates. Selected
product candidates are then advanced in its Pipeline Program to the
pre-IND stage. The Company's business model primarily involves
collaborations covering the further development and commercialization of
product candidates from its Pipeline Program and various forms of
research and discovery agreements, in both cases providing Compugen with
potential milestone payments and royalties on product sales or other
forms of revenue sharing. In 2012, Compugen established operations in
California for the development of oncology and immunology monoclonal
antibody therapeutic candidates against Compugen-discovered drug
targets. In 2002, Compugen established an affiliate, Evogene Ltd. (www.evogene.com)
(TASE:
EVGN.TA), to utilize certain of the Company's in silico predictive
discovery capabilities in agricultural biotechnology. For additional
information, please visit Compugen's corporate website at www.cgen.com.
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as “may”, “expects”, “anticipates”, “believes”, and “intends”, and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are discussed in the "Risk Factors" section Compugen’s Annual Report on Form 20-F for the year ended December 31, 2011 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Compugen’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.